AREXVY
RSV prefusion F protein, adjuvanted
120 mcg / 0.5 mL · powder for suspension · intramuscular · 50 years and older
RSV
RSV
AREXVY · ABRYSVO · MRESVIA
One dose for adults 75 and older, at-risk adults, or in pregnancy. Every product below is a Health Canada authorized vaccine; every schedule comes from the Canadian Immunization Guide.
- Products
- 3
- Dose schedules
- 4
- Guidance checked
- 2026-09-27
Authorized products
Brand names and DINs (Drug Identification Numbers) as Health Canada's Drug Product Database lists them. The product monograph is the manufacturer's full prescribing information approved by Health Canada.
ABRYSVO
RSV prefusion F protein (subgroups A and B)
60 mcg + 60 mcg / 0.5 mL · powder for solution · intramuscular · 18 years and older, and in pregnancy at 32 to 36 weeks
MRESVIA
RSV prefusion F protein mRNA
50 mcg / 0.5 mL · dispersion · intramuscular · 18 years and older
Before and after vaccination
- Bring your immunization record so earlier doses can be checked.
- Discuss a serious reaction to a previous vaccine, relevant health conditions, medicines and allergies before receiving a dose.
- After vaccination, stay where you can be observed for at least 15 minutes and report feeling faint or signs of an allergic reaction right away.
- Keep the vaccine name, date and dose in your immunization record.
Based on the Canadian Immunization Guide's administration practices and acute reactions guidance.
Pregnancy & breastfeeding
Pregnancy
ABRYSVO is recommended at 28 to 36 weeks of gestation, before or during RSV season (Health Canada authorizes 32 to 36 weeks). AREXVY and MRESVIA are not used in pregnancy.
Breastfeeding
Not recommended on the basis of breastfeeding alone; the maternal dose protects the infant when given during pregnancy.
Source: Immunization in pregnancy and breastfeeding: Canadian Immunization Guide — Chapter updated August 2026. Live vaccines are generally contraindicated in pregnancy; routinely recommended vaccines can be given while breastfeeding unless the chapter says otherwise.
How many doses
The schedules the Canadian Immunization Guide describes for this vaccine. Which one applies depends on age, health and product — use the dose planner to see the dates for your situation.
RSV — adults 75 and older, one dose
1 doseOne dose of RSV vaccine is recommended for all adults 75 years of age and older.
NACI recommends a single dose of RSV vaccine (AREXVY, ABRYSVO or MRESVIA) for all adults 75 years of age and older. Protection lasts at least 3 years; no repeat dose is currently recommended.
ProductsAREXVYABRYSVOMRESVIA
RSV — adults 65 to 74 at increased risk, one dose
1 doseOne dose is recommended for adults 65 to 74 with a condition that raises the risk of severe RSV disease.
NACI recommends a single dose for adults 65 to 74 who are at increased risk: chronic heart or lung disease (including COPD, asthma, cystic fibrosis), diabetes and metabolic disease, moderate or severe immunodeficiency, chronic kidney or liver disease, neurologic or neurodevelopmental conditions, class 3 obesity, or residence in a nursing home. Other adults 65 to 74 may consider it.
ProductsAREXVYABRYSVOMRESVIA
RSV — adults 18 to 64 at increased risk, one dose
1 doseOne dose is recommended for the highest-risk adults 18 and older, and may be considered for other adults at increased risk.
NACI recommends a single dose for adults 18 and older who live in a nursing home, have had a lung or stem-cell transplant, are on home oxygen or receive dialysis. Other adults 18 to 64 at increased risk of severe RSV disease may consider a single dose. AREXVY is authorized from 50 years; ABRYSVO and MRESVIA from 18.
ProductsAREXVYABRYSVOMRESVIA
RSV (ABRYSVO) in pregnancy — one dose
1 doseOne dose of ABRYSVO during pregnancy to protect the newborn; NACI recommends 28 to 36 weeks, the product is authorized for 32 to 36 weeks.
ABRYSVO only. NACI recommends one dose at 28 to 36 weeks of gestation, before or during the RSV season, at least 2 weeks before birth; Health Canada authorizes 32 to 36 weeks. There is no recommendation for a repeat dose in a later pregnancy; the infant can receive a monoclonal antibody instead.
ProductsABRYSVO
References and product information
- Respiratory syncytial virus (RSV) vaccines: Canadian Immunization Guide — Chapter updated May 2026
- Vaccine administration practices: Canadian Immunization Guide
- Anaphylaxis and other acute reactions: Canadian Immunization Guide
- Health Canada Drug Product Database — product records and monographs
- Pharmasist vaccine reference: AREXVY
- Pharmasist vaccine reference: ABRYSVO
- Pharmasist vaccine reference: MRESVIA — related brand reference; confirm the exact DIN
Clinical rules reviewed on 2026-09-27. General information from public Canadian guidance; a personal assessment is needed for treatment decisions. Care365 does not decide whether a vaccine is publicly funded in Ontario.